

# Synosis Therapeutics™

## BRIDGING THE DIVIDE

Synosis Therapeutics is focused on finding new treatments for disorders of the central nervous system, focusing initially on compounds with potential in neurological and psychiatric areas.

Central to our approach is the innovative use of medical techniques, including state-of-the-art imaging tools, in small, smart clinical trials to establish rapid proof-of-concept.

This approach will lead to a better understanding of a drug's action earlier in development than ever before and determine which molecules should progress into larger Phase 2b/3 studies.

Data from our proof-of-concept studies will also enable larger studies to be designed more effectively.

Our strategy will be to license a strong portfolio of compounds to facilitate the selection of the best molecules for development.

Synosis was launched in January 2007 and is backed by initial funding of \$32.5 million. It is headquartered in South San Francisco, California.

In January 2007, Synosis entered into a broad strategic agreement with Roche to in-license five clinical compounds.

### Our Pipeline

COMPOUNDS	preclinical	Phase 0*	Phase I	Phase II	Phase III	registration
<b>SYN-114</b> Cognitive Disorders			●			
<b>SYN-115</b> Parkinson's			●			
<b>SYN-116</b> Acute Pain			●			
<b>SYN-117</b> Drug Dependency			●			
<b>SYN-119</b> Drug dependency	●					

\*Compounds that have entered Good Laboratory Practice (GLP) and toxicology studies as part of preparations for entry into man.

Over the next few years, we will build one of the most promising pipelines of drug candidates in CNS development. Thanks to strong financial backing and an experienced management team, we have the capacity to deliver in a notoriously difficult area of drug development.

---

### Management Team

---

#### **Ian Massey, DPhil**

*President and Chief Executive Officer*

Ian Massey has over 30 years experience in drug discovery and development. Until recently, he was the Senior Vice President and Head of Research and Preclinical Development at Roche Palo Alto.



From 1995 to 2002, Ian held positions of increasing responsibility at Roche Bioscience including Senior Vice President, Head of Neurobiology Business Unit and Central Research & Development and Senior Vice President of Research and Preclinical Development.

---

#### **Mark Moran MD, MBA**

*Chief Medical Officer*

Mark Moran is a co-founder and Director of Synosis Therapeutics, having founded two other drug development companies since joining the pharmaceutical industry in 1986. Mark was founder and first Chief Scientific Officer of Intarcia Therapeutics in 1996 and co-founder of Amira Pharmaceuticals in 2005.



He has also served in a number of roles in research and development, including Senior Director of Clinical Research at Searle/Monsanto and Chief Medical Officer at Glycomed.

---

#### **Hervé Girsault MBA**

*Chief Business Officer*

Hervé Girsault has extensive experience in business development and licensing in the pharmaceutical industry.



Until July 2005, he held a number of senior positions at Novartis, including Senior Vice President and Global Head of Partnering and Out-Licensing at Novartis Pharma in Basel, Global Head of Business Development & Licensing for Novartis Consumer Health and General Manager of Novartis Consumer Health in Benelux.

---

**Tom Woiwode PhD**

Vice President, Business Development &amp; Strategy

Tom brings to Synosis an investment background, having joined Synosis from one of the founding investors, Versant Ventures. While at Versant, Tom wrote the business plan and negotiated the license agreements that led to the formation of Synosis. In collaboration with Brad Bolzon, a Managing Director at Versant, Tom enabled the formation of two additional early stage start-up companies: Amira Pharmaceuticals, where he served as the acting Chief Business Officer, and Sentient Therapeutics, where he continues to serve on the Board of Directors.

Prior to Versant, Tom worked as a medicinal chemist at XenoPort on methods to improve the gastrointestinal absorption of drug candidates. In this role, he led the development of a new high-throughput screening technology to enable the identification of pathways capable of transporting large molecule therapeutics across the gastrointestinal barrier.

Tom graduated from UC Berkeley summa cum laude with highest honors for his BA in English and earned the Departmental Citation for his BSc in Chemistry. Tom went on to earn his PhD in Organic Chemistry as an NSF Fellow at Stanford University.

**David Greenwood PhD**

European Director of Clinical Science

David Greenwood is a neuropsychopharmacologist, who specialises in both the discovery and clinical development of drugs, targeting the central nervous system.

From 1995 to 1999, David was Director, CNS Projects, at Shire Pharmaceuticals and during the previous 25 years held various senior positions in Zeneca and the former ICI Pharmaceuticals, including Clinical Pharmacology Studies Manager and in-house Phase I Unit Operations Manager, CNS Clinical Projects Manager and CNS Preclinical Project Leader.

**Jay Shukert MBA**

Chief Financial Officer

Jay Shukert has over 10 years of experience as a consultant CFO to biotechnology and medical device companies. In this role, he has managed equity and debt financings, raising more than \$235 million, developed strategic plans, implemented financial strategies and developed product evaluation methods.

Previously, Jay held senior finance positions at CV Therapeutics, Neurex Corporation, Genentech and Arthur Andersen.



---

**Board of Directors**

---

Bradley Bolzon PhD  
*Chairman of the Board, Managing Director, Versant Ventures*

Ian Massey DPhil  
*President and CEO, Synosis Therapeutics*

Hervé Girsault MBA  
*CBO, Synosis Therapeutics*

Mark Moran MD MBA  
*CMO, Synosis Therapeutics*

Andrew Sandham BSc  
*Venture Partner, Abingworth*

Andrew Schwab BS  
*Founder and Managing Partner, 5AM Ventures*

Heath Lukatch PhD  
*Novo A/S*

---

**Founding Investors**

---

Versant Ventures  
5AM  
Abingworth  
Novo A/S

---

**Areas of Development**

---

Parkinson's Disease  
Drug dependency  
Acute pain  
Cognitive disorders

---

**Contact**

---

Synosis Therapeutics  
601 Gateway Boulevard  
Suite 1200  
South San Francisco, CA 94080, USA

Tel: +1 650 244 4850  
Fax: +1 650 244 4874

[www.synosis.com](http://www.synosis.com)

For any further information, please contact Vice President of Operations, Mike Mulqueen, at: [mmulqueen@synosis.com](mailto:mmulqueen@synosis.com)